Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
For cell therapies to transition from promises to products, increased efforts need to be put into the identification of the factors and biological mechanisms that affect safety and efficacy, and into the design of cost-effective methods for the harvesting, expansion, manipulation and purification of the cells.
This focus provides an overview of the state of the art of cell therapies, with emphasis on cardiac regenerative medicine and immunotherapy, and explores the challenges that lie ahead.
This Perspective provides an overview of recent cardiac cell therapies and their limitations, and argues for the need of deeper mechanistic understanding that informs the use of cells and of next-generation cell-free biologics in cardiac regeneration.
This Review discusses the manufacturing of cell products for clinically advanced cell therapies, and highlights potential manufacturing bottlenecks and solutions towards the cost-effective commercialization of the therapies.
This Review Article provides an overview of chimeric antigen receptors (CARs) for T cells and discusses engineering strategies for the design of next-generation CAR-T therapies for haematologic and solid cancers.
For cell therapies to transition from promises to products, increased efforts need to be put into the identification of the factors and biological mechanisms that affect safety and efficacy, and into the design of cost-effective methods for the harvesting, expansion, manipulation and purification of the cells.
An epicardial device that enables sustained and repeated administration of small molecules, macromolecules and cells directly to the epicardium provides therapeutic benefits in a rat model of myocardial infarction.